Clinical Trials
5 trialsNCT05987241 2026-06-03
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06204614 2026-05-18
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Enrolling by invitation
NCT05700227 2026-04-21
ARTIA-Bladder
Varian, a Siemens Healthineers Company
Phase NA Terminated
NCT06809140 2026-02-23
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06257017 2025-04-04
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
The University of Hong Kong
Phase 2 Recruiting